Sigma Nutrition Radio #596: Why Do Omega-3 Trials Show Mixed Results?
14 snips
Mar 3, 2026 Alan Flanagan, a nutrition scientist and educator who interprets clinical and mechanistic evidence, unpacks why omega-3 trials give mixed results. He breaks down trial design, dose, population risk and outcome choices. Short segments explore historical narratives, mechanisms like triglyceride effects, and why subgroup patterns and dosing explain much of the conflict.
AI Snips
Chapters
Transcript
Episode notes
Inuit Origin Story Is Not Solid Evidence
- Early Inuit reports linking high omega-3 intake to low heart disease were anecdotal and not prospective evidence.
- Alan Flanagan explains Bang and Dyerberg relied on medical record anecdotes, and modern data show Inuit have high stroke and lower life expectancy.
Triglyceride Lowering Is The Key Mechanism
- The dominant plausible mechanism for EPA/DHA benefit is triglyceride lowering and its downstream effects on lipoprotein remodeling.
- Alan details how high TGs force LDL to become small dense and overburden HDL, increasing atherogenic risk.
Null Primary Trials Still Hid Important Benefits
- Large primary prevention trials VITAL and ASCEND used ~1 g/day and reported null primary composites but showed subgroup benefits.
- Danny and Alan note VITAL reduced myocardial infarction by ~28% despite no overall composite effect.